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Background
Pro-B-Type Natriuretic Peptide (ProBNP), from which
biologically active BNP and inactive amino-terminal BNP
(NT-proBNP) are processed, has recently been reported to
be elevated in patients with heart failure (HF). It remains
to be shown in a large cohort study whether ProBNP cir-
culates in normals, what factors influence ProBNP, and
whether or not it is a sensitive biomarker for left ventricu-
lar (LV) dysfunction.
We test whether a novel assay (BioRad) for ProBNP will be
specific for ProBNP and not cross react with other forms
of BNP. Furthermore, we hypothesize that ProBNP levels
will be most determined by age and gender and that
ProBNP will be a sensitive and specific biomarker for LV
dysfunction in the general community.
Methods
We used a large community cohort (n = 2009; age => 45)
from Olmsted County, MN. All subjects had detailed
echocardiography, clinical phenotyping, and assessment
of comorbidities. ProBNP was measured using BioRad
assay. Univariable and multivariable analysis were used to
determine which clinical factors best determine ProBNP
levels in all subjects. ROC curves were generated by com-
paring ProBNP to 2-D Doppler Echocardiography in
detecting LV dysfunction. Assay specificity was assessed by
adding 8 different forms of BNP to normal human
plasma.
Results
ProBNP was present in normals (median male = 10 pg/
ml, female = 20; p < .001) and elevated in those with
EF<40% (median male = 195, female = 188; n = 36). Gen-
der and age (Spearman > .3, p < .01) were strong predic-
tors of Pro-BNP. ProBNP was a sensitive and specific
marker for LV dysfunction based on ROC curves
(AUC=.86). Finally, the BioRad assay did not cross react
with any BNP forms that we added to normal human
plasma.
Conclusion
Using a novel ProBNP assay, we are the first to establish
normal ProBNP levels in a large general adult population,
suggesting that the normal human heart secretes ProBNP.
We conclude that age and gender should be considered in
interpretation of ProBNP values, similar to BNP and NT-
proBNP. Importantly, in the entire population of ran-
domly selected adults in the general community, ProBNP
was a sensitive and specific biomarker for the detection of
LV dysfunction. Thus, these studies establish the utility of
ProBNP as a biomarker for HF, and we suggest further
studies to better establish the biologic and pathophysio-
logic significance of ProBNP in humans.
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